Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Mattison

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 15, 2024
Functionality of bone marrow mesenchymal stromal cells derived from head and neck cancer patients - A FDA-IND enabling study regarding MSC-based treatments for radiation-induced xerostomiaGrace C Blitzer, Cristina Paz, Annemarie Glassey, et al.
Blood Advances|February 11, 2026
Conventional Therapy vs HMA or LDAC ± Venetoclax in Older Adults With AML: Systematic Review and Meta-analysisSara Ibrahim, Barbara Burgos-Mansilla, Yetiani Roldan, et al.
Cancer|December 1, 2020
Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemiaTalha Badar, Aniko Szabo, Shira Dinner, et al.
Leukemia & Lymphoma|November 12, 2025
Early assessment of treatment response in AML using FLT PET/cT: a trial of the ECOG-ACRIN Cancer Research Group (EAI141)Robert Jeraj, Fenghai Duan, Ryan J Mattison, et al.
Blood Advances|January 15, 2026
Antileukemic therapies for older adults with AML ineligible for conventional therapy: systematic review & meta-analysisMaria Jose Oliveros, Saifur R Chowdhury, Yetiani Roldan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 16, 2019
Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019Patrick A Brown, Matthew Wieduwilt, Aaron Logan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 16, 2024
Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyBijal Shah, Ryan J Mattison, Ramzi Abboud, et al.
Blood Advances|December 1, 2025
American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adultsMikkael A Sekeres, Ryan J Mattison, Andrew S Artz, et al.
Cancer Discovery|February 17, 2021
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic LymphomaVinod A Pullarkat, Norman J Lacayo, Elias Jabbour, et al.
Blood|May 30, 2025
Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignanciesArmin Ghobadi, Ibrahim Aldoss, Shannon L Maude, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 15, 2024
Functionality of bone marrow mesenchymal stromal cells derived from head and neck cancer patients - A FDA-IND enabling study regarding MSC-based treatments for radiation-induced xerostomiaGrace C Blitzer, Cristina Paz, Annemarie Glassey, et al.
Blood Advances|February 11, 2026
Conventional Therapy vs HMA or LDAC ± Venetoclax in Older Adults With AML: Systematic Review and Meta-analysisSara Ibrahim, Barbara Burgos-Mansilla, Yetiani Roldan, et al.
Cancer|December 1, 2020
Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemiaTalha Badar, Aniko Szabo, Shira Dinner, et al.
Leukemia & Lymphoma|November 12, 2025
Early assessment of treatment response in AML using FLT PET/cT: a trial of the ECOG-ACRIN Cancer Research Group (EAI141)Robert Jeraj, Fenghai Duan, Ryan J Mattison, et al.
Blood Advances|January 15, 2026
Antileukemic therapies for older adults with AML ineligible for conventional therapy: systematic review & meta-analysisMaria Jose Oliveros, Saifur R Chowdhury, Yetiani Roldan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 16, 2019
Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019Patrick A Brown, Matthew Wieduwilt, Aaron Logan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 16, 2024
Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyBijal Shah, Ryan J Mattison, Ramzi Abboud, et al.
Blood Advances|December 1, 2025
American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adultsMikkael A Sekeres, Ryan J Mattison, Andrew S Artz, et al.
Cancer Discovery|February 17, 2021
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic LymphomaVinod A Pullarkat, Norman J Lacayo, Elias Jabbour, et al.
Blood|May 30, 2025
Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignanciesArmin Ghobadi, Ibrahim Aldoss, Shannon L Maude, et al.
Pageof 8